

Company Announcements Office
ASX Limited

24 April 2019

Dear Sir/Madam

Cleansing Notice under section 708A of the *Corporations Act 2001 (Cth)*

On 2 April 2019, Sienna Cancer Diagnostics Limited, (ASX: **SDX**) ("**Sienna**" or "**the Company**") announced that it had entered into a binding agreement for the purchase of certain assets from Sevident Inc relating to a unique technology to capture and isolate exosomes and other biomarkers for use in tests such as liquid biopsies for cancer.

Sienna has now completed the Sevident acquisition and has issued 21,665,764 fully paid ordinary shares in the Company as part of the purchase consideration.

Sienna gives this cleansing notice (**Notice**) under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**). The new ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this Notice, the Company has complied with:

- the provisions of Chapter 2M of the Corporations Act as they apply to Sienna; and
- section 674 of the Corporations Act (continuous disclosure obligations).

As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

For further information, please visit our website (www.siennadiagnostics.com.au) or contact the Company on (03) 8288 2141 between the hours of 9am and 5pm AEST.

Yours faithfully



Tony Di Pietro
Company Secretary
Sienna Cancer Diagnostics Limited.

ENDS





About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna's strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners.

The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.

About Sevident

Based in the San Francisco Bay Area, Sevident Inc. was founded in 2008 with one key goal in mind: Developing a revolutionary way of producing a range of powerful molecular diagnostics from a single, dynamic technology. While their primary focus has been in the area of sample preparation for cancer IVD testing through the isolation and capture of molecular and cellular targets, the Sevident technology is also applicable to additional fields such as infectious disease and agricultural pathogens.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

